Eli Lilly: TOGETHER-PsA Study Meets Primary Endpoint At 36 Weeks
I'm PortAI, I can summarize articles.
Eli Lilly and Company (LLY) announced positive topline results from the TOGETHER-PsA Phase 3b trial, which evaluated the use of Taltz and Zepbound in adults with active psoriatic arthritis and obesity. At 36 weeks, 31.7% of patients receiving both treatments achieved a 50% improvement in PsA activity and at least 10% weight reduction, compared to 0.8% on Taltz alone. Detailed results will be presented at a medical meeting, and topline results from the TOGETHER-PsO trial are expected in early 2026.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: rttnews The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments